The cognitive effects of endocrine therapy in survivors of breast cancer: A prospective longitudinal study up to 6 years after treatment
ConclusionsIn the current observational cohort study, no detrimental effect of ET on cognitive function was identified in survivors of early ‐stage breast cancer receiving treatment with ET compared with those who were not. (Source: Cancer)
Source: Cancer - November 28, 2018 Category: Cancer & Oncology Authors: Kathleen Van Dyk, Catherine M. Crespi, Julienne E. Bower, Steven A. Castellon, Laura Petersen, Patricia A. Ganz Tags: Original Article Source Type: research

Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center
ConclusionsAmong AJ patients found to have a pathogenic mutation on genetic assessment, approximately 22.8% had a mutation that would be missed with BRCA1/2 AJ founder mutation testing. Comprehensive multigene panel sequencing can provide clinically relevant genetic information for AJ patients and should be considered for genetic assessment in this population. (Source: Cancer)
Source: Cancer - November 27, 2018 Category: Cancer & Oncology Authors: Melissa K. Frey, Rohini V. Kopparam, Zhen Ni Zhou, Jessica C. Fields, Ama Buskwofie, Ann D. Carlson, Thomas Caputo, Kevin Holcomb, Eloise Chapman ‐Davis Tags: Original Article Source Type: research

Trends in liver cancer mortality in the United States: Dual burden among foreign ‐ and US‐born persons
ConclusionsEfforts that address the major risk factors for liver cancer are needed to help to alleviate the health disparities observed among foreign ‐born individuals and reverse the increasing trend observed in the US‐born population. (Source: Cancer)
Source: Cancer - November 27, 2018 Category: Cancer & Oncology Authors: Meheret Endeshaw, Benjamin D. Hallowell, Hilda Razzaghi, Virginia Senkomago, Matthew T. McKenna, Mona Saraiya Tags: Original Article Source Type: research

Safety and survival outcomes for bloodless transplantation in patients with myeloma
High ‐dose therapy (HDT) and autologous stem cell transplantation (ASCT) are established components in the treatment of multiple myeloma; however, undergoing transplantation usually requires hematopoietic support, which poses a challenge among patients who are unwilling to receive blood products. Most transplant centers decline HDT/ASCT to these patients because of safety concerns. Here, the authors’ institutional data on safety, engraftment parameters, and survival outcomes after bloodless ASCT (BL‐ASCT) are examined among patients with myeloma. This retrospective case‐control study includ ed patients who unde...
Source: Cancer - November 27, 2018 Category: Cancer & Oncology Authors: Nisha S. Joseph, Jonathan L. Kaufman, Lawrence H. Boise, Kelly Valla, Dhwani K. Almaula, Chikaodili O. Obidike, Amelia A. Langston, Edmund K. Waller, Hanna J. Khoury, Christopher R. Flowers, Michael Graiser, Leonard T. Heffner, Sagar Lonial, Tags: Review Article Source Type: research

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery
ConclusionsThese findings indicate that aneuploidy ‐related and leukemia‐specific alterations cooperate to tolerate an abnormal chromosome number in AML, and they point to the mitotic and protein degradation machineries as potential therapeutic targets. (Source: Cancer)
Source: Cancer - November 27, 2018 Category: Cancer & Oncology Authors: Giorgia Simonetti, Antonella Padella, Italo Far ìa do Valle, Maria Chiara Fontana, Eugenio Fonzi, Samantha Bruno, Carmen Baldazzi, Viviana Guadagnuolo, Marco Manfrini, Anna Ferrari, Stefania Paolini, Cristina Papayannidis, Giovanni Marconi, Tags: Original Article Source Type: research

Issue Information
Cancer, Volume 124, Issue 21, Page 4107-4114, November 1, 2018. (Source: Cancer)
Source: Cancer - November 26, 2018 Category: Cancer & Oncology Tags: Issue Information Source Type: research

First Person: Hyman Muss, MD
Cancer, Volume 124, Issue 21, Page 4115-4116, November 1, 2018. (Source: Cancer)
Source: Cancer - November 26, 2018 Category: Cancer & Oncology Authors: Carrie Printz Tags: CancerScope Source Type: research

Cancer centers issue call to action regarding the human papillomavirus vaccine
Cancer, Volume 124, Issue 21, Page 4117-4117, November 1, 2018. (Source: Cancer)
Source: Cancer - November 26, 2018 Category: Cancer & Oncology Authors: Carrie Printz Tags: CancerScope Source Type: research

STAR act expected to improve care for pediatric patients with cancer
Cancer, Volume 124, Issue 21, Page 4116-4117, November 1, 2018. (Source: Cancer)
Source: Cancer - November 26, 2018 Category: Cancer & Oncology Authors: Carrie Printz Tags: CancerScope Source Type: research

Cognitive performance in survivors of breast cancer and markers of biological aging
BackgroundBiological aging pathways accelerated by cancer treatments may be a mechanism for cognitive impairment in cancer survivors. The goal of the current study was to examine whether indicators of biological aging, namely elevated levels of DNA damage, reduced telomerase enzymatic activity, and shorter peripheral blood mononuclear cell (PBMC) telomere length (TL) would be related to cognitive function in a cohort of survivors of breast cancer.MethodsThe authors evaluated a cross ‐sectional sample of 94 women aged 36 to 69 years who were treated for early‐stage breast cancer 3 to 6 years previously. Leukocyte DNA da...
Source: Cancer - November 26, 2018 Category: Cancer & Oncology Authors: Judith E. Carroll, Kathleen Van Dyk, Julienne E. Bower, Zorica Scuric, Laura Petersen, Robert Schiestl, Michael R. Irwin, Patricia A. Ganz Tags: Original Article Source Type: research

Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer
BackgroundThe standard of care for patients with resected stage I to stage III pancreatic ductal adenocarcinoma (PDAC) is adjuvant gemcitabine ‐based chemotherapy. The role of adjuvant treatment in patients with subcentimeter, stage IA PDAC is unknown. The current study evaluated the effect of adjuvant treatment on survival outcomes among patients with American Joint Committee on Cancer/International Union Against Cancer stage IA (T1N0) resected PDAC using the National Cancer Data Base (NCDB).MethodsA retrospective review of the NCDB was conducted for patients diagnosed with T1 (tumor limited to the pancreas and measurin...
Source: Cancer - November 20, 2018 Category: Cancer & Oncology Authors: Walid L. Shaib, Amit Surya Narayan, Jeffrey M. Switchenko, Sujata R. Kane, Christina Wu, Mehmet Akce, Olatunji B. Alese, Pretesh R. Patel, Shishir K Maithel, Juan M. Sarmiento, David A. Kooby, Bassel F. El ‐Rayes Tags: Original Article Source Type: research

Outcomes of secondary solid tumor malignancies among patients with myeloma: A population ‐based study
ConclusionsThe results of the current study support curative treatment approaches to secondary cancers among patients with myeloma while highlighting the need for ongoing active myeloma management. (Source: Cancer)
Source: Cancer - November 19, 2018 Category: Cancer & Oncology Authors: Peter Barth, Jorge J. Castillo, Adam J. Olszewski Tags: Original Article Source Type: research

Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer
CONCLUSIONSRace/ethnicity, neighborhood SES, and insurance status appear to be significantly associated with receipt of surgical ADT. Future research will need to characterize other differences in initial treatments among men with advanced prostate cancer based on race/ethnicity and aim to better understand what factors drive the association between surgical ADT among men of Hispanic origin or those from areas with low neighborhood SES. (Source: Cancer)
Source: Cancer - November 16, 2018 Category: Cancer & Oncology Authors: Hala T. Borno, Daphne Y. Lichtensztajn, Scarlett L. Gomez, Nynikka R. Palmer, Charles J. Ryan Tags: Original Article Source Type: research

Prevalence of comorbidities and effect on survival in survivors of human papillomavirus –related and human papillomavirus–unrelated head and neck cancer in the United States
ConclusionsThere is a large burden of comorbidities in both patients with HPV ‐related and HPV‐unrelated HNC, both of which are associated with decreased survival. Oncologic surveillance should not be limited to the evaluation of disease status, but also should include screening for the highly prevalent conditions associated with the risk of death. (Source: Cancer)
Source: Cancer - November 16, 2018 Category: Cancer & Oncology Authors: Danielle F. Eytan, Amanda L. Blackford, David W. Eisele, Carole Fakhry Tags: Original Article Source Type: research

Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer
CONCLUSIONSRace/ethnicity, neighborhood SES, and insurance status appear to be significantly associated with receipt of surgical ADT. Future research will need to characterize other differences in initial treatments among men with advanced prostate cancer based on race/ethnicity and aim to better understand what factors drive the association between surgical ADT among men of Hispanic origin or those from areas with low neighborhood SES. (Source: Cancer)
Source: Cancer - November 16, 2018 Category: Cancer & Oncology Authors: Hala T. Borno, Daphne Y. Lichtensztajn, Scarlett L. Gomez, Nynikka R. Palmer, Charles J. Ryan Tags: Original Article Source Type: research

Reply to Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Serban Negoita, Angela Mariotto, Vicki Benard, Betsy A. Kohler, Ahmedin Jemal, Lynne Penberthy Tags: Correspondence Source Type: research

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration ‐resistant prostate cancer
ConclusionsTreatment with abiraterone acetate without steroids is feasible, although clinically significant adverse events can occur in a minority of patients. The use of abiraterone acetate without prednisone should be balanced with the potential for toxicity and requires close monitoring. (Source: Cancer)
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Rana R. McKay, Lillian Werner, Susanna J. Jacobus, Alexandra Jones, Elahe A. Mostaghel, Brett T. Marck, Atish D. Choudhury, Mark M. Pomerantz, Christopher J. Sweeney, Susan F. Slovin, Michael J. Morris, Philip W. Kantoff, Mary ‐Ellen Taplin Tags: Original Article Source Type: research

Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Susan J. Curry, Alex H. Krist, Douglas K. Owens Tags: Correspondence Source Type: research

Ethical considerations about emergent surgical hospitalizations in patients with advanced cancer
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Katherine C. Lee, Zara Cooper Tags: Cancer Case Conundrums Source Type: research

Regional differences in gallbladder cancer pathogenesis: Insights from a multi ‐institutional comparison of tumor mutations
AbstractBackgroundAlthough rare in the United States, gallbladder cancer (GBCA) is a common cause of cancer death in some parts of the world. To investigate regional differences in pathogenesis and outcomes for GBCA, tumor mutations were analyzed from a sampling of specimens.MethodsPrimary tumors from patients with GBCA who were treated in Chile, Japan, and the United States between 1999 and 2016 underwent targeted sequencing of known cancer ‐associated genes. Fisher exact and Kruskal‐Wallis tests assessed differences in clinicopathologic and genetic factors. Kaplan‐Meier methods evaluated differences in overall surv...
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Raja R. Narayan, John M. Creasy, Debra A. Goldman, Mithat G önen, Cyriac Kandoth, Ritika Kundra, David B. Solit, Gokce Askan, David S. Klimstra, Olca Basturk, Peter J. Allen, Vinod P. Balachandran, Michael I. D’Angelica, Ronald P. DeMatteo Tags: Original Article Source Type: research

Does race predict the development of metastases in men who receive androgen ‐deprivation therapy for a biochemical recurrence after radical prostatectomy?
In this study among men who underwent radical prostatectomy (RP), African American men (AAM) were 28% more likely to develop recurrent disease compared with Caucasian men (CM). However, among those who had nonmetastatic, castration ‐resistant prostate cancer (CRPC), race did not predict metastases or overall survival. Whether race predicts metastases among men who receive androgen‐deprivation therapy (ADT) after a biochemical recurrence (BCR) (ie, before CRPC but after BCR) is untested.MethodsThe authors identified 595 AAM and CM who received ADT for a BCR that developed after RP between 1988 and 2015 in the Shared Equ...
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Adriana C. Vidal, Lauren E. Howard, Amanda De Hoedt, Christopher J. Kane, Martha K. Terris, William J. Aronson, Matthew R. Cooperberg, Christopher L. Amling, Stanislav Lechpammer, Scott C. Flanders, Stephen J. Freedland Tags: Original Article Source Type: research

Reply to Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Serban Negoita, Angela Mariotto, Vicki Benard, Betsy A. Kohler, Ahmedin Jemal, Lynne Penberthy Tags: Correspondence Source Type: research

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration ‐resistant prostate cancer
ConclusionsTreatment with abiraterone acetate without steroids is feasible, although clinically significant adverse events can occur in a minority of patients. The use of abiraterone acetate without prednisone should be balanced with the potential for toxicity and requires close monitoring. (Source: Cancer)
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Rana R. McKay, Lillian Werner, Susanna J. Jacobus, Alexandra Jones, Elahe A. Mostaghel, Brett T. Marck, Atish D. Choudhury, Mark M. Pomerantz, Christopher J. Sweeney, Susan F. Slovin, Michael J. Morris, Philip W. Kantoff, Mary ‐Ellen Taplin Tags: Original Article Source Type: research

Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Susan J. Curry, Alex H. Krist, Douglas K. Owens Tags: Correspondence Source Type: research

Ethical considerations about emergent surgical hospitalizations in patients with advanced cancer
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Katherine C. Lee, Zara Cooper Tags: Cancer Case Conundrums Source Type: research

Regional differences in gallbladder cancer pathogenesis: Insights from a multi ‐institutional comparison of tumor mutations
AbstractBackgroundAlthough rare in the United States, gallbladder cancer (GBCA) is a common cause of cancer death in some parts of the world. To investigate regional differences in pathogenesis and outcomes for GBCA, tumor mutations were analyzed from a sampling of specimens.MethodsPrimary tumors from patients with GBCA who were treated in Chile, Japan, and the United States between 1999 and 2016 underwent targeted sequencing of known cancer ‐associated genes. Fisher exact and Kruskal‐Wallis tests assessed differences in clinicopathologic and genetic factors. Kaplan‐Meier methods evaluated differences in overall surv...
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Raja R. Narayan, John M. Creasy, Debra A. Goldman, Mithat G önen, Cyriac Kandoth, Ritika Kundra, David B. Solit, Gokce Askan, David S. Klimstra, Olca Basturk, Peter J. Allen, Vinod P. Balachandran, Michael I. D’Angelica, Ronald P. DeMatteo Tags: Original Article Source Type: research

Does race predict the development of metastases in men who receive androgen ‐deprivation therapy for a biochemical recurrence after radical prostatectomy?
In this study among men who underwent radical prostatectomy (RP), African American men (AAM) were 28% more likely to develop recurrent disease compared with Caucasian men (CM). However, among those who had nonmetastatic, castration ‐resistant prostate cancer (CRPC), race did not predict metastases or overall survival. Whether race predicts metastases among men who receive androgen‐deprivation therapy (ADT) after a biochemical recurrence (BCR) (ie, before CRPC but after BCR) is untested.MethodsThe authors identified 595 AAM and CM who received ADT for a BCR that developed after RP between 1988 and 2015 in the Shared Equ...
Source: Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Adriana C. Vidal, Lauren E. Howard, Amanda De Hoedt, Christopher J. Kane, Martha K. Terris, William J. Aronson, Matthew R. Cooperberg, Christopher L. Amling, Stanislav Lechpammer, Scott C. Flanders, Stephen J. Freedland Tags: Original Article Source Type: research

Iron overload in patients with myelodysplastic syndromes: An updated overview
Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal hematopoietic stem cell disorders characterized by a broad clinical spectrum related to ineffective hematopoiesis leading to unilineage or multilineage cytopenias, with a high propensity for transformation to acute myeloid leukemia. Iron overload has been recently identified as one of the important conditions complicating the management of these diverse disorders. The accumulation of iron is mainly related to chronic transfusions; however, evidence suggests a possible role for ineffective erythropoiesis and increased intestinal absorption of iron, re...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Nour M. Moukalled, Fuad A. El Rassi, Sally N. Temraz, Ali T. Taher Tags: Review Article Source Type: research

Gut microbiota ‐immune‐brain interactions in chemotherapy‐associated behavioral comorbidities
Increasing scientific attention is focused on the gut ‐brain axis, including the ability of the gastrointestinal (GI) tract to modulate central nervous system function. Changes in the intestinal microbiome can influence affective‐like behavior, cognitive performance, fatigue, and sleep in rodents and humans. Patients with cancer who are receiving c hemotherapy experience similar negative behavioral changes and concurrent GI symptoms. These chemotherapy comorbidities can be long‐lasting and may reduce patients' quality of life and motivation to comply with treatment. This review summarizes the clinical and preclinical...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Kelley R. Jordan, Brett R. Loman, Michael T. Bailey, Leah M. Pyter Tags: Review Article Source Type: research

Issue Information
Cancer, Volume 124, Issue 20, Page 3951-3958, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Tags: Issue Information Source Type: research

Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de ‐implementation
Cancer, Volume 124, Issue 20, Page 3971-3974, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Ted A. Skolarus, Megan EV Caram, Christina H. Chapman, David C. Smith, Brent K. Hollenbeck, Sarah Hawley, Alexander Tsodikov, Anne Sales, Daniela Wittmann, Alexander Zaslavsky Tags: Editorial Source Type: research

Socioeconomics, race, and ethnicity in childhood cancer survival: Accessing and addressing root causes of disparities
Cancer, Volume 124, Issue 20, Page 3975-3978, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Meryl D. Colton, Makenzie Hawkins, DeLayna Goulding, Myles Cockburn, Adam L. Green Tags: Editorial Source Type: research

On the humane side of medicine
Cancer, Volume 124, Issue 20, Page 3969-3970, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Fadlo R. Khuri Tags: Editorial Source Type: research

Will my child do better if she enrolls in a clinical trial?
The question of whether children with cancer who enroll in clinical trials have superior outcomes compared with those who do not participate has been pursued for more than 4 decades, and recent studies have provided conflicting answers. Whether clinical trial participation influences outcome has important implications for how clinicians should present trial participation to patients and families. Methodological challenges limit generalizations about the impact of clinical trial participation on outcome compared with nonparticipation. Oncologists should inform patients and families that clinical trials are the engine for fu...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Malcolm A. Smith, Steven Joffe Tags: Commentary Source Type: research

Does socioeconomic status account for racial and ethnic disparities in childhood cancer survival?
ConclusionsSES significantly mediates racial/ethnic childhood cancer survival disparities for several cancers. However, the proportion of the total race/ethnicity –survival association explained by SES varies between black‐white and Hispanic‐white comparisons for some cancers, and this suggests that mediation by other factors differs across groups. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Rebecca D. Kehm, Logan G. Spector, Jenny N. Poynter, David M. Vock, Sean F. Altekruse, Theresa L. Osypuk Tags: Original Article Source Type: research

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4 ‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial
ConclusionsThe sustained PFS benefit and long ‐term safety of ELd at 4 years, similar to those observed at 2 and 3 years, support ELd as a valuable therapeutic option for the long‐term treatment of patients with RRMM. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Meletios A. Dimopoulos, Sagar Lonial, Keith A. Betts, Clara Chen, Miriam L. Zichlin, Alexander Brun, James E. Signorovitch, Dinara Makenbaeva, Sabeen Mekan, Oumar Sy, Katja Weisel, Paul G. Richardson Tags: Original Article Source Type: research

A prospective comparison of cancer clinical trial availability and enrollment among adolescents/young adults treated at an adult cancer hospital or affiliated children ’s hospital
The objective of this study was to evaluate whether differences in CCT availability related to treatment site could explain the low CCT enrollment.MethodsThis prospective, observational cohort study was conducted at an academic children ’s hospital and its affiliated but geographically separated adult cancer hospital within a National Cancer Institute‐designated Comprehensive Cancer Center. For consecutive, newly diagnosed AYA patients, it was determined whether an appropriate CCT existed nationally, was available at the treatm ent site, and was used for enrollment. Proportions of AYAs in these categories were comp...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Stefanie M. Thomas, Jemily Malvar, Hanh Henry Tran, Jared T. Shows, David R. Freyer Tags: Original Article Source Type: research

Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Background:Men with locally advanced prostate cancer (LAPCa) or regionally advanced prostate cancer (RAPCa) are at high risk for death from their disease. Clinical guidelines support multimodal approaches, which include radical prostatectomy (RP) followed by radiotherapy (XRT) and XRT plus androgen deprivation therapy (ADT). However, there are limited data comparing these substantially different treatment approaches. Using Surveillance, Epidemiology, and End Results (SEER) –Medicare data, this study compared survival outcomes and adverse effects associated with RP plus XRT versus XRT plus ADT in these men.Methods:SEE...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan D. Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A. Singer, Mark N. Stein, James A. Eastham, Peter T. Scardino, Yong Lin, Isaac Y. Kim, Grace L. Lu ‐Yao Tags: Original Article Source Type: research

GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers
The objectives of the current study were: 1) to determineGNA* aberration status in a cohort of 1348 patients with cancer and 2) to examine tumor mutational burden, overall survival rates, and treatment outcomes in patients withGNA* ‐positive tumors versus those with tumors that had wild‐typeGNA*.MethodsFor each patient, clinical and genomic data were collected from medical records. Next ‐generation sequencing was performed for each patient (range, 182‐236 genes).ResultsAberrations ofGNA* genes were identified in a subset of patients who had 8 of the 12 cancer types examined, and a significant association was observ...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Austin J. Parish, Vi Nguyen, Aaron M. Goodman, Karthikeyan Murugesan, Garrett M. Frampton, Razelle Kurzrock Tags: Original Article Source Type: research

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini ‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage
ConclusionsThe combination of inotuzumab and low ‐intensity mini‐HCVD chemotherapy with or without blinatumomab shows encouraging results in patients with ALL in first salvage. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Elias Jabbour, Koji Sasaki, Farhad Ravandi, Xuelin Huang, Nicholas J. Short, Maria Khouri, Partow Kebriaei, Jan Burger, Joseph Khoury, Jeffrey Jorgensen, Nitin Jain, Marina Konopleva, Guillermo Garcia ‐Manero, Tapan Kadia, Jorge Cortes, J Tags: Original Article Source Type: research

Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study
ConclusionsImatinib plus everolimus showed a limited activity in progressing advanced chordoma. Interestingly, the amount of tumor cells activated for mammalian target of rapamycin effectors correlated with the response. Toxicity was not negligible. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Silvia Stacchiotti, Carlo Morosi, Salvatore Lo Vullo, Alessandra Casale, Elena Palassini, Anna Maria Frezza, Gabriella Dinoi, Antonella Messina, Alessandro Gronchi, Adalberto Cavalleri, Elisabetta Venturelli, Daniele Morelli, Silvana Pilotti, Tags: Original Article Source Type: research

Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial
AbstractBackgroundThe current study reports rates of knowledge regarding the probability of aBRCA1 and/orS pathogenic variant and genetic testing in patients with breast cancer, collected as part of a randomized controlled trial of a tailored, comprehensive, and interactive decision tool (iCanDecide).MethodsA total of 537 patients newly diagnosed with early ‐stage breast cancer were enrolled at the time of their first visit in 22 surgical practices, and were surveyed 5 weeks (496 patients; Response Rate [RR], 92%) after enrollment after treatment decision making. Primary outcomes included knowledge regarding the probabil...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Michele C. Gornick, Allison W. Kurian, Lawrence C. An, Angela Fagerlin, Reshma Jagsi, Steven J. Katz, Sarah T. Hawley Tags: Original Article Source Type: research

Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging
This study compared the survival outcomes of patients with stage III, node ‐positive disease (pT123N1M0) and patients with stage III, node ‐negative disease (pT3N0M0).MethodsA database of 4652 patients with RCC of any histological subtype treated with surgery at The University of Texas MD Anderson Cancer Center from 1993 to 2012 was retrospectively assessed. A total of 115 patients with pT123N1M0 disease, 274 patients with pT3N0M0 disease, and 523 patients with pT123N0/xM1 disease were included. Overall survival (OS) and cancer ‐specific survival (CSS) were estimated and compared between each cohort.ResultsMedian OS ...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Kai ‐Jie Yu, Sarp K. Keskin, Matthew A. Meissner, Firas G. Petros, Xuemei Wang, Leonardo D. Borregales, Cindy Gu, Pheroze Tamboli, Surena F. Matin, Christopher G. Wood, Jose A. Karam Tags: Original Article Source Type: research

Enrollment on clinical trials does not improve survival for children with acute myeloid leukemia: A population ‐based study
ConclusionsEnrollment on a clinical trial was not associated with improved survival for children with AML in a population ‐based cohort. Rationale for trial enrollment should not include the likelihood of benefit compared with non‐enrollment. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Tony H. Truong, Jason D. Pole, Randy Barber, David Dix, Ketan P. Kulkarni, Emilie Martineau, Alicia Randall, David Stammers, Caron Strahlendorf, Douglas Strother, Lillian Sung Tags: Original Article Source Type: research

Suicide risk among cancer survivors: Head and neck versus other cancers
ConclusionsAlthough survival rates in cancer have improved because of improved treatments, the risk of death by suicide remains a problem for cancer survivors, particularly those with HNC. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Nosayaba Osazuwa ‐Peters, Matthew C. Simpson, Longwen Zhao, Eric Adjei Boakye, Stephanie I. Olomukoro, Teresa Deshields, Travis M. Loux, Mark A. Varvares, Mario Schootman Tags: Original Article Source Type: research

Cancer stem cells in esophageal cancer and response to therapy
Cancer, Volume 124, Issue 20, Page 3962-3964, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Kazuto Harada, Melissa Pool Pizzi, Hideo Baba, Namita D. Shanbhag, Shumei Song, Jaffer A. Ajani Tags: Insight from the Experts Source Type: research

Older melanoma patients may respond better to anti ‐PD1 immunotherapy
Cancer, Volume 124, Issue 20, Page 3961-3961, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Tags: CancerScope Source Type: research

Lifestyle ‐related cancers increase, highlight need for prevention
Cancer, Volume 124, Issue 20, Page 3960-3961, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Tags: CancerScope Source Type: research

US Food and Drug Administration considers comments on proposed nicotine product regulations
Cancer, Volume 124, Issue 20, Page 3959-3960, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Carrie Printz Tags: CancerScope Source Type: research